Immune modulating peptides for the treatment and suppression of multiple sclerosis

Clinical Immunology

Volumn 144, Issue 2, 2012, Pages 127-138

  Badawi, Ahmed H ^a   Siahaan, Teruna J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

Antigen; Bifunctional peptide inhibitor; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Peptide

Indexed keywords

ALLERGEN; ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CYTOKINE; DIRUCOTIDE; FINGOLIMOD; GAMMA INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INDUCIBLE T CELL COSTIMULATOR LIGAND; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 12; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MITOXANTRONE; MYELIN; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN[68-88]; MYELIN BASIC PROTEIN[85-96]; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN[41-60]; NATALIZUMAB; PEPTIDE; PROTEOLIPID PROTEIN; T LYMPHOCYTE RECEPTOR; TIPLIMOTIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN PRESENTING CELL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL TYPE; CENTRAL NERVOUS SYSTEM; CEREBROSPINAL FLUID; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DENDRITIC CELL; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HISTOPATHOLOGY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL PARAMETERS; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; MACROPHAGE; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPROTECTION; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RECEPTOR DOWN REGULATION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SPECIFIC IMMUNOTHERAPY; T LYMPHOCYTE; TH17 CELL; TH2 CELL;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; PEPTIDES;

EID: 84862297459     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.05.010     Document Type: Review

References (161)

1. Lassmann H. Classification of demyelinating diseases at the interface between etiology and pathogenesis. Curr. Opin. Neurol. 2001, 14:253-258.
2. McFarland H.F., Martin R. Multiple sclerosis: a complicated picture of autoimmunity. Nat. Immunol. 2007, 8:913-919.
3. Compston A. The genetic epidemiology of multiple sclerosis. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1999, 354:1623-1634.
4. Lincoln M.R., Montpetit A., Cader M.Z., Saarela J., Dyment D.A., Tiislar M., Ferretti V., Tienari P.J., Sadovnick A.D., Peltonen L., Ebers G.C., Hudson T.J. A predominant role for the HLA class II region in the association of the MHC region with multiple sclerosis. Nat. Genet. 2005, 37:1108-1112.
5. Sospedra M., Martin R. Immunology of multiple sclerosis. Annu. Rev. Immunol. 2005, 23:683-747.
6. Pender M.P. Does Epstein-Barr virus infection in the brain drive the development of multiple sclerosis?. Brain 2009, 132:3196-3198.
7. Bagert B.A. Epstein-Barr virus in multiple sclerosis. Curr. Neurol. Neurosci. Rep. 2009, 9:405-410.
8. Gilden D.H. Infectious causes of multiple sclerosis. Lancet Neurol. 2005, 4:195-202.
9. Gaydos C.A. Chlamydia pneumoniae and its proposed link to multiple sclerosis: to be or not to be?. Neurology 2001, 56:1126-1127.
10. Jacobson S., Cross A. Association of Chlamydia pneumoniae and multiple sclerosis: stage two?. Neurology 2001, 56:1128-1129.
11. Yao S.Y., Ljunggren-Rose A., Stratton C.W., Mitchell W.M., Sriram S. Regulation by IFN-beta of inducible nitric oxide synthase and interleukin-12/p40 in murine macrophages cultured in the presence of Chlamydia pneumoniae antigens. J. Interferon Cytokine Res. 2001, 21:137-146.
12. Kenealy S.J., Pericak-Vance M.A., Haines J.L. The genetic epidemiology of multiple sclerosis. J. Neuroimmunol. 2003, 143:7-12.
13. Ormerod I.E., Miller D.H., McDonald W.I., du Boulay E.P., Rudge P., Kendall B.E., Moseley I.F., Johnson G., Tofts P.S., Halliday A.M., et al. The role of NMR imaging in the assessment of multiple sclerosis and isolated neurological lesions. A quantitative study. Brain 1987, 110(Pt. 6):1579-1616.
14. van Walderveen M.A., Kamphorst W., Scheltens P., van Waesberghe J.H., Ravid R., Valk J., Polman C.H., Barkhof F. Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 1998, 50:1282-1288.
15. Yong V.W., Chabot S., Stuve O., Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology 1998, 51:682-689.
16. Derwenskus J. Current disease-modifying treatment of multiple sclerosis. Mt. Sinai J. Med. 2011, 78:161-175.
17. Arnon R. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunol. Lett. 1996, 50:1-15.
18. Ransohoff R.M. Natalizumab for multiple sclerosis. N. Engl. J. Med. 2007, 356:2622-2629.
19. Horga A., Castillo J., Montalban X. Fingolimod for relapsing multiple sclerosis: an update. Expert Opin. Pharmacother. 2010, 11:1183-1196.
20. Stoeckle C., Tolosa E. Antigen processing and presentation in multiple sclerosis. Results Probl. Cell Differ. 2010, 51:149-172.
21. Goodnow C.C., Sprent J., Fazekas de St Groth B., Vinuesa C.G. Cellular and genetic mechanisms of self tolerance and autoimmunity. Nature 2005, 435:590-597.
22. Butcher E.C., Picker L.J. Lymphocyte homing and homeostasis. Science 1996, 272:60-66.
23. Ransohoff R.M., Kivisakk P., Kidd G. Three or more routes for leukocyte migration into the central nervous system. Nat. Rev. Immunol. 2003, 3:569-581.
24. Goverman J. Autoimmune T cell responses in the central nervous system. Nat. Rev. Immunol. 2009, 9:393-407.
25. Marty M.C., Alliot F., Rutin J., Fritz R., Trisler D., Pessac B. The myelin basic protein gene is expressed in differentiated blood cell lineages and in hemopoietic progenitors. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:8856-8861.
26. Karman J., Ling C., Sandor M., Fabry Z. Initiation of immune responses in brain is promoted by local dendritic cells. J. Immunol. 2004, 173:2353-2361.
27. Hatterer E., Touret M., Belin M.F., Honnorat J., Nataf S. Cerebrospinal fluid dendritic cells infiltrate the brain parenchyma and target the cervical lymph nodes under neuroinflammatory conditions. PLoS One 2008, 3:e3321.
28. Serafini B., Rosicarelli B., Magliozzi R., Stigliano E., Capello E., Mancardi G.L., Aloisi F. Dendritic cells in multiple sclerosis lesions: maturation stage, myelin uptake, and interaction with proliferating T cells. J. Neuropathol. Exp. Neurol. 2006, 65:124-141.
29. Greter M., Heppner F.L., Lemos M.P., Odermatt B.M., Goebels N., Laufer T., Noelle R.J., Becher B. Dendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis. Nat. Med. 2005, 11:328-334.
30. McMahon E.J., Bailey S.L., Castenada C.V., Waldner H., Miller S.D. Epitope spreading initiates in the CNS in two mouse models of multiple sclerosis. Nat. Med. 2005, 11:335-339.
31. Hauser S.L., Waubant E., Arnold D.L., Vollmer T., Antel J., Fox R.J., Bar-Or A., Panzara M., Sarkar N., Agarwal S., Langer-Gould A., Smith C.H. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N. Engl. J. Med. 2008, 358:676-688.
32. Kabat E.A., Freedman D.A., et al. A study of the crystalline albumin, gamma globulin and total protein in the cerebrospinal fluid of 100 cases of multiple sclerosis and in other diseases. Am. J. Med. Sci. 1950, 219:55-64.
33. Lock C., Hermans G., Pedotti R., Brendolan A., Schadt E., Garren H., Langer-Gould A., Strober S., Cannella B., Allard J., Klonowski P., Austin A., Lad N., Kaminski N., Galli S.J., Oksenberg J.R., Raine C.S., Heller R., Steinman L. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 2002, 8:500-508.
34. Goverman J., Perchellet A., Huseby E.S. The role of CD8(+) T cells in multiple sclerosis and its animal models. Curr. Drug Targets Inflamm. Allergy 2005, 4:239-245.
35. Friese M.A., Fugger L. Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy?. Brain 2005, 128:1747-1763.
36. Junker A., Ivanidze J., Malotka J., Eiglmeier I., Lassmann H., Wekerle H., Meinl E., Hohlfeld R., Dornmair K. Multiple sclerosis: T-cell receptor expression in distinct brain regions. Brain 2007, 130:2789-2799.
37. Crawford M.P., Yan S.X., Ortega S.B., Mehta R.S., Hewitt R.E., Price D.A., Stastny P., Douek D.C., Koup R.A., Racke M.K., Karandikar N.J. High prevalence of autoreactive, neuroantigen-specific CD8+ T cells in multiple sclerosis revealed by novel flow cytometric assay. Blood 2004, 103:4222-4231.
38. Coles A.J., Cox A., Le Page E., Jones J., Trip S.A., Deans J., Seaman S., Miller D.H., Hale G., Waldmann H., Compston D.A. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J. Neurol. 2006, 253:98-108.
39. Perchellet A., Brabb T., Goverman J.M. Crosspresentation by nonhematopoietic and direct presentation by hematopoietic cells induce central tolerance to myelin basic protein. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:14040-14045.
40. Grakoui A., Bromley S.K., Sumen C., Davis M.M., Shaw A.S., Allen P.M., Dustin M.L. The immunological synapse: a molecular machine controlling T cell activation. Science 1999, 285:221-227.
41. Tseng S.Y., Dustin M.L. T-cell activation: a multidimensional signaling network. Curr. Opin. Cell Biol. 2002, 14:575-580.
42. Jonuleit H., Schmitt E., Schuler G., Knop J., Enk A.H. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 2000, 192:1213-1222.
43. Larche M., Wraith D.C. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat. Med. 2005, 11:S69-S76.
44. Jenkins M.K., Johnson J.G. Molecules involved in T-cell costimulation. Curr. Opin. Immunol. 1993, 5:361-367.
45. June C.H., Bluestone J.A., Nadler L.M., Thompson C.B. The B7 and CD28 receptor families. Immunol. Today 1994, 15:321-331.
46. Schonbeck U., Libby P. The CD40/CD154 receptor/ligand dyad. Cell. Mol. Life Sci. 2001, 58:4-43.
47. Girvin A.M., Dal Canto M.C., Miller S.D. CD40/CD40L interaction is essential for the induction of EAE in the absence of CD28-mediated co-stimulation. J. Autoimmun. 2002, 18:83-94.
48. McCoy K.D., Le Gros G. The role of CTLA-4 in the regulation of T cell immune responses. Immunol. Cell Biol. 1999, 77:1-10.
49. Valitutti S., Dessing M., Aktories K., Gallati H., Lanzavecchia A. Sustained signaling leading to T cell activation results from prolonged T cell receptor occupancy. Role of T cell actin cytoskeleton. J. Exp. Med. 1995, 181:577-584.
50. Wiendl H., Neuhaus O., Mehling M., Wintterle S., Schreiner B., Mitsdoerffer M., Wienhold W., Weissert R., Wessels J., Hartung H.P., Weller M., Tolosa E., Melms A. The CD28 related molecule ICOS: T cell modulation in the presence and absence of B7.1/2 and regulational expression in multiple sclerosis. J. Neuroimmunol. 2003, 140:177-187.
51. Miyamoto K., Kingsley C.I., Zhang X., Jabs C., Izikson L., Sobel R.A., Weiner H.L., Kuchroo V.K., Sharpe A.H. The ICOS molecule plays a crucial role in the development of mucosal tolerance. J. Immunol. 2005, 175:7341-7347.
52. Galicia G., Kasran A., Uyttenhove C., De Swert K., Van Snick J., Ceuppens J.L. ICOS deficiency results in exacerbated IL-17 mediated experimental autoimmune encephalomyelitis. J. Clin. Immunol. 2009, 29:426-433.
53. Lee K.H., Holdorf A.D., Dustin M.L., Chan A.C., Allen P.M., Shaw A.S. T cell receptor signaling precedes immunological synapse formation. Science 2002, 295:1539-1542.
54. van der Merwe P.A. Formation and function of the immunological synapse. Curr. Opin. Immunol. 2002, 14:293-298.
55. Gutcher I., Becher B. APC-derived cytokines and T cell polarization in autoimmune inflammation. J. Clin. Invest. 2007, 117:1119-1127.
56. Cannella B., Raine C.S. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 1995, 37:424-435.
57. Hirsch R.L., Panitch H.S., Johnson K.P. Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferon in vitro. J. Clin. Immunol. 1985, 5:386-389.
58. Maimone D., Reder A.T., Gregory S. T cell lymphokine-induced secretion of cytokines by monocytes from patients with multiple sclerosis. Cell. Immunol. 1993, 146:96-106.
59. Merrill J.E., Strom S.R., Ellison G.W., Myers L.W. In vitro study of mediators of inflammation in multiple sclerosis. J. Clin. Immunol. 1989, 9:84-96.
60. Selmaj K., Raine C.S., Cannella B., Brosnan C.F. Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J. Clin. Invest. 1991, 87:949-954.
61. Ozenci V., Kouwenhoven M., Huang Y.M., Kivisakk P., Link H. Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment. Clin. Exp. Immunol. 2000, 120:147-153.
62. Mouzaki A., Tselios T., Papathanassopoulos P., Matsoukas I., Chatzantoni K. Immunotherapy for multiple sclerosis: basic insights for new clinical strategies. Curr. Neurovasc. Res. 2004, 1:325-340.
63. Racke M.K. Experimental autoimmune encephalomyelitis (EAE). Curr. Protoc. Neurosci. 2001, (Chapter 9, Unit9.7).
64. Constantinescu C.S., Hilliard B.A. Adjuvants in EAE. Experimental Models of Multiple Sclerosis 2005, 73-84. Springer. C.S.C. Ehud Lavi (Ed.).
65. Waldner H., Whitters M.J., Sobel R.A., Collins M., Kuchroo V.K. Fulminant spontaneous autoimmunity of the central nervous system in mice transgenic for the myelin proteolipid protein-specific T cell receptor. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:3412-3417.
66. Gold R., Linington C., Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain 2006, 129:1953-1971.
67. Teitelbaum D., Meshorer A., Hirshfeld T., Arnon R., Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur. J. Immunol. 1971, 1:242-248.
68. Lublin F.D., Lavasa M., Viti C., Knobler R.L. Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin. Immunol. Immunopathol. 1987, 45:122-128.
69. Yednock T.A., Cannon C., Fritz L.C., Sanchez-Madrid F., Steinman L., Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992, 356:63-66.
70. Chiba K., Kataoka H., Seki N., Shimano K., Koyama M., Fukunari A., Sugahara K., Sugita T. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-beta in mouse experimental autoimmune encephalomyelitis. Int. Immunopharmacol. 2011, 11:366-372.
71. Chun J., Hartung H.P. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin. Neuropharmacol. 2010, 33:91-101.
72. Papadopoulos D., Rundle J., Patel R., Marshall I., Stretton J., Eaton R., Richardson J.C., Gonzalez M.I., Philpott K.L., Reynolds R. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses. J. Neurosci. Res. 2010, 88:346-359.
73. Kataoka H., Sugahara K., Shimano K., Teshima K., Koyama M., Fukunari A., Chiba K. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration. Cell. Mol. Immunol. 2005, 2:439-448.
74. Fujino M., Funeshima N., Kitazawa Y., Kimura H., Amemiya H., Suzuki S., Li X.K. Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J. Pharmacol. Exp. Ther. 2003, 305:70-77.
75. Baker D., Gerritsen W., Rundle J., Amor S. Critical appraisal of animal models of multiple sclerosis. Mult. Scler. 2011, 17:647-657.
76. Baxter A.G. The origin and application of experimental autoimmune encephalomyelitis. Nat. Rev. Immunol. 2007, 7:904-912.
77. Noon L. Prophylactic inoculation against hay fever. Historical document. Ann. Allergy 1960, 18:287-291.
78. Durham S.R., Walker S.M., Varga E.M., Jacobson M.R., O'Brien F., Noble W., Till S.J., Hamid Q.A., Nouri-Aria K.T. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 1999, 341:468-475.
79. Bousquet J., Lockey R., Malling H.J., Alvarez-Cuesta E., Canonica G.W., Chapman M.D., Creticos P.J., Dayer J.M., Durham S.R., Demoly P., Goldstein R.J., Ishikawa T., Ito K., Kraft D., Lambert P.H., Lowenstein H., Muller U., Norman P.S., Reisman R.E., Valenta R., Valovirta E., Yssel H. Allergen immunotherapy: therapeutic vaccines for allergic diseases. World Health Organization. American academy of Allergy, Asthma and Immunology. Ann. Allergy Asthma Immunol. 1998, 81:401-405.
80. Akdis C.A., Akdis M., Blesken T., Wymann D., Alkan S.S., Muller U., Blaser K. Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J. Clin. Invest. 1996, 98:1676-1683.
81. Jones S.M., Pons L., Roberts J.L., Scurlock A.M., Perry T.T., Kulis M., Shreffler W.G., Steele P., Henry K.A., Adair M., Francis J.M., Durham S., Vickery B.P., Zhong X., Burks A.W. Clinical efficacy and immune regulation with peanut oral immunotherapy. J. Allergy Clin. Immunol. 2009, 124:292-300.
82. Skripak J.M., Nash S.D., Rowley H., Brereton N.H., Oh S., Hamilton R.G., Matsui E.C., Burks A.W., Wood R.A. A randomized, double-blind, placebo-controlled study of milk oral immunotherapy for cow's milk allergy. J. Allergy Clin. Immunol. 2008, 122:1154-1160.
83. Mobs C., Slotosch C., Loffler H., Jakob T., Hertl M., Pfutzner W. Birch pollen immunotherapy leads to differential induction of regulatory T cells and delayed helper T cell immune deviation. J. Immunol. 2010, 184:2194-2203.
84. Sabatos-Peyton C.A., Verhagen J., Wraith D.C. Antigen-specific immunotherapy of autoimmune and allergic diseases. Curr. Opin. Immunol. 2010, 22:609-615.
85. McDevitt H. Specific antigen vaccination to treat autoimmune disease. Proc. Natl. Acad. Sci. U. S. A. 2004, 101(Suppl. 2):14627-14630.
86. Friedman A., Weiner H.L. Induction of anergy or active suppression following oral tolerance is determined by antigen dosage. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:6688-6692.
87. Faria A.M., Weiner H.L. Oral tolerance: mechanisms and therapeutic applications. Adv. Immunol. 1999, 73:153-264.
88. Weiner H.L., Friedman A., Miller A., Khoury S.J., Al-Sabbagh A., Santos L., Sayegh M., Nussenblatt R.B., Trentham D.E., Hafler D.A. Oral tolerance: immunologic mechanisms and treatment of animal and human organ-specific autoimmune diseases by oral administration of autoantigens. Annu. Rev. Immunol. 1994, 12:809-837.
89. Bitar D.M., Whitacre C.C. Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. Cell. Immunol. 1988, 112:364-370.
90. Meyer A.L., Benson J.M., Gienapp I.E., Cox K.L., Whitacre C.C. Suppression of murine chronic relapsing experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein. J. Immunol. 1996, 157:4230-4238.
91. Higgins P.J., Weiner H.L. Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein and its fragments. J. Immunol. 1988, 140:440-445.
92. Javed N.H., Gienapp I.E., Cox K.L., Whitacre C.C. Exquisite peptide specificity of oral tolerance in experimental autoimmune encephalomyelitis. J. Immunol. 1995, 155:1599-1605.
93. Al-Sabbagh A., Miller A., Santos L.M., Weiner H.L. Antigen-driven tissue-specific suppression following oral tolerance: orally administered myelin basic protein suppresses proteolipid protein-induced experimental autoimmune encephalomyelitis in the SJL mouse. Eur. J. Immunol. 1994, 24:2104-2109.
94. Karpus W.J., Kennedy K.J., Smith W.S., Miller S.D. Inhibition of relapsing experimental autoimmune encephalomyelitis in SJL mice by feeding the immunodominant PLP139-151 peptide. J. Neurosci. Res. 1996, 45:410-423.
95. Faria A.M., Weiner H.L. Oral tolerance. Immunol. Rev. 2005, 206:232-259.
96. Bai X.F., Shi F.D., Xiao B.G., Li H.L., van der Meide P.H., Link H. Nasal administration of myelin basic protein prevents relapsing experimental autoimmune encephalomyelitis in DA rats by activating regulatory cells expressing IL-4 and TGF-beta mRNA. J. Neuroimmunol. 1997, 80:65-75.
97. Bai X.F., Li H.L., Shi F.D., Liu J.Q., Xiao B.G., Van der Meide P.H., Link H. Complexities of applying nasal tolerance induction as a therapy for ongoing relapsing experimental autoimmune encephalomyelitis (EAE) in DA rats. Clin. Exp. Immunol. 1998, 111:205-210.
98. Metzler B., Wraith D.C. Mucosal tolerance in a murine model of experimental autoimmune encephalomyelitis. Ann. N. Y. Acad. Sci. 1996, 778:228-242.
99. Anderton S.M., Wraith D.C. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur. J. Immunol. 1998, 28:1251-1261.
100. Leadbetter E.A., Bourque C.R., Devaux B., Olson C.D., Sunshine G.H., Hirani S., Wallner B.P., Smilek D.E., Happ M.P. Experimental autoimmune encephalomyelitis induced with a combination of myelin basic protein and myelin oligodendrocyte glycoprotein is ameliorated by administration of a single myelin basic protein peptide. J. Immunol. 1998, 161:504-512.
101. Staykova M.A., Simmons R.D., Willenborg D.O. Infusion of soluble myelin basic protein protects long-term against induction of experimental autoimmune encephalomyelitis. Immunol. Cell Biol. 1997, 75:54-64.
102. Gaur A., Wiers B., Liu A., Rothbard J., Fathman C.G. Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 1992, 258:1491-1494.
103. Warren K.G., Catz I., Ferenczi L.Z., Krantz M.J. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA Class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5years of follow-up treatment. Eur. J. Neurol. 2006, 13:887-895.
104. Warren K.G., Catz I., Wucherpfennig K.W. Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J. Neurol. Sci. 1997, 152:31-38.
105. Bynoe M.S., Evans J.T., Viret C., Janeway C.A. Epicutaneous immunization with autoantigenic peptides induces T suppressor cells that prevent experimental allergic encephalomyelitis. Immunity 2003, 19:317-328.
106. Szczepanik M., Tutaj M., Bryniarski K., Dittel B.N. Epicutaneously induced TGF-beta-dependent tolerance inhibits experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2005, 164:105-114.
107. Jurynczyk M., Walczak A., Jurewicz A., Jesionek-Kupnicka D., Szczepanik M., Selmaj K. Immune regulation of multiple sclerosis by transdermally applied myelin peptides. Ann. Neurol. 2010, 68:593-601.
108. Santambrogio L., Sato A.K., Fischer F.R., Dorf M.E., Stern L.J. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:15050-15055.
109. Miller S.D., Turley D.M., Podojil J.R. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat. Rev. Immunol. 2007, 7:665-677.
110. Kumar V., Urban J.L., Horvath S.J., Hood L. Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties: T-cell activation, major histocompatibility complex binding, and ability to block experimental allergic encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:1337-1341.
111. Karin N., Mitchell D.J., Brocke S., Ling N., Steinman L. Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of interferon gamma and tumor necrosis factor alpha production. J. Exp. Med. 1994, 180:2227-2237.
112. Gaur A., Boehme S.A., Chalmers D., Crowe P.D., Pahuja A., Ling N., Brocke S., Steinman L., Conlon P.J. Amelioration of relapsing experimental autoimmune encephalomyelitis with altered myelin basic protein peptides involves different cellular mechanisms. J. Neuroimmunol. 1997, 74:149-158.
113. Nicholson L.B., Greer J.M., Sobel R.A., Lees M.B., Kuchroo V.K. An altered peptide ligand mediates immune deviation and prevents autoimmune encephalomyelitis. Immunity 1995, 3:397-405.
114. Nicholson L.B., Murtaza A., Hafler B.P., Sette A., Kuchroo V.K. A T cell receptor antagonist peptide induces T cells that mediate bystander suppression and prevent autoimmune encephalomyelitis induced with multiple myelin antigens. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:9279-9284.
115. Young D.A., Lowe L.D., Booth S.S., Whitters M.J., Nicholson L., Kuchroo V.K., Collins M. IL-4, IL-10, IL-13, and TGF-beta from an altered peptide ligand-specific Th2 cell clone down-regulate adoptive transfer of experimental autoimmune encephalomyelitis. J. Immunol. 2000, 164:3563-3572.
116. Kuchroo V.K., Greer J.M., Kaul D., Ishioka G., Franco A., Sette A., Sobel R.A., Lees M.B. A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J. Immunol. 1994, 153:3326-3336.
117. Franco A., Southwood S., Arrhenius T., Kuchroo V.K., Grey H.M., Sette A., Ishioka G.Y. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur. J. Immunol. 1994, 24:940-946.
118. Crowe P.D., Qin Y., Conlon P.J., Antel J.P. NBI-5788, an altered MBP83-99 peptide, induces a T-helper 2-like immune response in multiple sclerosis patients. Ann. Neurol. 2000, 48:758-765.
119. Bielekova B., Goodwin B., Richert N., Cortese I., Kondo T., Afshar G., Gran B., Eaton J., Antel J., Frank J.A., McFarland H.F., Martin R. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat. Med. 2000, 6:1167-1175.
120. Kappos L., Comi G., Panitch H., Oger J., Antel J., Conlon P., Steinman L. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat. Med. 2000, 6:1176-1182.
121. Aharoni R., Teitelbaum D., Arnon R., Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:634-639.
122. Ruiz P.J., DeVoss J.J., Nguyen L.V., Fontoura P.P., Hirschberg D.L., Mitchell D.J., Garcia K.C., Steinman L. Immunomodulation of experimental autoimmune encephalomyelitis with ordered peptides based on MHC-TCR binding motifs. J. Immunol. 2001, 167:2688-2693.
123. Illes Z., Stern J.N., Reddy J., Waldner H., Mycko M.P., Brosnan C.F., Ellmerich S., Altmann D.M., Santambrogio L., Strominger J.L., Kuchroo V.K. Modified amino acid copolymers suppress myelin basic protein 85-99-induced encephalomyelitis in humanized mice through different effects on T cells. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11749-11754.
124. Stern J.N., Illes Z., Reddy J., Keskin D.B., Fridkis-Hareli M., Kuchroo V.K., Strominger J.L. Peptide 15-mers of defined sequence that substitute for random amino acid copolymers in amelioration of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:1620-1625.
125. Munari L., Lovati R., Boiko A. Therapy with glatiramer acetate for multiple sclerosis. Cochrane Database Syst. Rev. 2004, CD004678.
126. Manikwar P., Kiptoo P., Badawi A.H., Buyuktimkin B., Siahaan T.J. Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases. Med. Res. Rev. 2011, (Electronic publication ahead of print Mar. 23) http://dx.doi.org/10.1002/med.20243.
127. Corper A.L., Stratmann T., Apostolopoulos V., Scott C.A., Garcia K.C., Kang A.S., Wilson I.A., Teyton L. A structural framework for deciphering the link between I-Ag7 and autoimmune diabetes. Science 2000, 288:505-511.
128. Xu C.R., Yusuf-Makagiansar H., Hu Y., Jois S.D., Siahaan T.J. Structural and ICAM-1-docking properties of a cyclic peptide from the I-domain of LFA-1: an inhibitor of ICAM-1/LFA-1-mediated T-cell adhesion. J. Biomol. Struct. Dyn. 2002, 19:789-799.
129. Casasnovas J.M., Stehle T., Liu J.H., Wang J.H., Springer T.A. A dimeric crystal structure for the N-terminal two domains of intercellular adhesion molecule-1. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4134-4139.
130. Bella J., Kolatkar P.R., Marlor C.W., Greve J.M., Rossmann M.G. The structure of the two amino-terminal domains of human ICAM-1 suggests how it functions as a rhinovirus receptor and as an LFA-1 integrin ligand. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:4140-4145.
131. Murray J.S., Oney S., Page J.E., Kratochvil-Stava A., Hu Y., Makagiansar I.T., Brown J.C., Kobayashi N., Siahaan T.J. Suppression of type 1 diabetes in NOD mice by bifunctional peptide inhibitor: modulation of the immunological synapse formation. Chem. Biol. Drug Des. 2007, 70:227-236.
132. Kobayashi N., Kobayashi H., Gu L., Malefyt T., Siahaan T.J. Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. J. Pharmacol. Exp. Ther. 2007, 322:879-886.
133. Kobayashi N., Kiptoo P., Kobayashi H., Ridwan R., Brocke S., Siahaan T.J. Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. Clin. Immunol. 2008, 129:69-79.
134. Ridwan R., Kiptoo P., Kobayashi N., Weir S., Hughes M., Williams T., Soegianto R., Siahaan T.J. Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor: structure optimization and pharmacokinetics. J. Pharmacol. Exp. Ther. 2010, 332:1136-1145.
135. Zhao H., Kiptoo P., Williams T.D., Siahaan T.J., Topp E.M. Immune response to controlled release of immunomodulating peptides in a murine experimental autoimmune encephalomyelitis (EAE) model. J. Control. Release 2010, 141:145-152.
136. Srinivasan M., Gienapp I.E., Stuckman S.S., Rogers C.J., Jewell S.D., Kaumaya P.T., Whitacre C.C. Suppression of experimental autoimmune encephalomyelitis using peptide mimics of CD28. J. Immunol. 2002, 169:2180-2188.
137. Chen J., He Q., Zhang R., Chu Y., Wang Y., Liu Q., Xiong S. Allogenic donor splenocytes pretreated with antisense peptide against B7 prolong cardiac allograft survival. Clin. Exp. Immunol. 2004, 138:245-250.
138. Marini J.C., Jameson B.A., Lublin F.D., Korngold R. A CD4-CDR3 peptide analog inhibits both primary and secondary autoreactive CD4+ T cell responses in experimental allergic encephalomyelitis. J. Immunol. 1996, 157:3706-3715.
139. Edling A.E., Choksi S., Huang Z., Korngold R. Effect of a cyclic heptapeptide based on the human CD4 domain 1 CC' loop region on murine experimental allergic encephalomyelitis: inhibition of both primary and secondary responses. J. Neuroimmunol. 2001, 112:115-128.
140. Iyer S., Lahana R., Buelow R. Rational design and development of RDP58. Curr. Pharm. Des. 2002, 8:2217-2229.
141. Cuturi M.C., Christoph F., Woo J., Iyer S., Brouard S., Heslan J.M., Pignon P., Soulillou J.P., Buelow R. RDP1258, a new rationally designed immunosuppressive peptide, prolongs allograft survival in rats: analysis of its mechanism of action. Mol. Med. 1999, 5:820-832.
142. Iyer S., Woo J., Cornejo M.C., Gao L., McCoubrey W., Maines M., Buelow R. Characterization and biological significance of immunosuppressive peptide D2702.75-84(E→V) binding protein. Isolation of heme oxygenase-1. J. Biol. Chem. 1998, 273:2692-2697.
143. Liu Y., Zhu B., Luo L., Li P., Paty D.W., Cynader M.S. Heme oxygenase-1 plays an important protective role in experimental autoimmune encephalomyelitis. Neuroreport 2001, 12:1841-1845.
144. Liu Y., Zhu B., Wang X., Luo L., Li P., Paty D.W., Cynader M.S. Bilirubin as a potent antioxidant suppresses experimental autoimmune encephalomyelitis: implications for the role of oxidative stress in the development of multiple sclerosis. J. Neuroimmunol. 2003, 139:27-35.
145. DeVry C.G., Valdez M., Gao L., Wang J., Kotsch K., Volk H.D., Bechmann I., Buelow R., Iyer S. RDP58, a novel immunomodulatory peptide, ameliorates clinical signs of disease in the Lewis rat model of acute experimental autoimmune encephalomyelitis. J. Neuroimmunol. 2004, 152:33-43.
146. Brodsky B., Erlanger-Rosengarten A., Proscura E., Shapira E., Wormser U. From topical antidote against skin irritants to a novel counter-irritating and anti-inflammatory peptide. Toxicol. Appl. Pharmacol. 2008, 229:342-350.
147. Shapira E., Brodsky B., Proscura E., Nyska A., Erlanger-Rosengarten A., Wormser U. Amelioration of experimental autoimmune encephalitis by novel peptides: involvement of T regulatory cells. J. Autoimmun. 2010, 35:98-106.
148. Zheng H.M., Jiang Y., Wang J.R., Gong X.L., Guo B.Y. Mimic peptides bonding specifically with the first and second extracellular loops of the CC chemokine receptor 5 derived from a phage display peptide library are potent inhibitors of experimental autoimmune encephalomyelitis. Inflamm. Res. 2011, 60:759-767.
149. Hamann I., Zipp F., Infante-Duarte C. Therapeutic targeting of chemokine signaling in Multiple Sclerosis. J. Neurol. Sci. 2008, 274:31-38.
150. Bielekova B., Becker B.L. Monoclonal antibodies in MS: mechanisms of action. Neurology 2010, 74(Suppl. 1):S31-S40.
151. Srinivasan M., Janardhanam S. Novel p65 binding GILZ peptide suppresses experimental autoimmune encephalomyelitis. J. Biol. Chem. 2011, 286:44799-44810.
152. Ayroldi E., Migliorati G., Bruscoli S., Marchetti C., Zollo O., Cannarile L., D'Adamio F., Riccardi C. Modulation of T-cell activation by the glucocorticoid-induced leucine zipper factor via inhibition of nuclear factor kappaB. Blood 2001, 98:743-753.
153. Marta M. Toll-like receptors in multiple sclerosis mouse experimental models. Ann. N. Y. Acad. Sci. 2009, 1173:458-462.
154. Weiner H.L. Multiple sclerosis is an inflammatory T-cell-mediated autoimmune disease. Arch. Neurol. 2004, 61:1613-1615.
155. Racke M.K., Drew P.D. Toll-like receptors in multiple sclerosis. Curr. Top. Microbiol. Immunol. 2009, 336:155-168.
156. Gambuzza M., Licata N., Palella E., Celi D., Foti Cuzzola V., Italiano D., Marino S., Bramanti P. Targeting toll-like receptors: emerging therapeutics for multiple sclerosis management. J. Neuroimmunol. 2011.
157. Bochner B.S., Lichtenstein L.M. Anaphylaxis. N. Engl. J. Med. 1991, 324:1785-1790.
158. Martin T.R., Galli S.J., Katona I.M., Drazen J.M. Role of mast cells in anaphylaxis. Evidence for the importance of mast cells in the cardiopulmonary alterations and death induced by anti-IgE in mice. J. Clin. Invest. 1989, 83:1375-1383.
159. Smith C.E., Eagar T.N., Strominger J.L., Miller S.D. Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:9595-9600.
160. Pedotti R., Mitchell D., Wedemeyer J., Karpuj M., Chabas D., Hattab E.M., Tsai M., Galli S.J., Steinman L. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat. Immunol. 2001, 2:216-222.
161. Katz D.H., Bargatze R.F., Bogowitz C.A., Katz L.R. Regulation of IgE antibody production by serum molecules. IV. Complete Freund's adjuvant induces both enhancing and suppressive activities detectable in the serum of low and high responder mice. J. Immunol. 1979, 122:2184-2190.